1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Grants for Research on Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional) is sponsored by National Institutes of Health. This federal grant supports exploratory and developmental research projects focused on biomarkers or composite biomarkers for neurological and neuromuscular disorders.
It aims to catalyze research programs that improve health outcomes for patients with these conditions.
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:PAR-25-024 Funding Opportunity Title:Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Health Expected Number of Awards: Assistance Listings:93.
853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders Cost Sharing or Matching Requirement:No Last Updated Date:Oct 28, 2024 Original Closing Date for Applications:Jan 07, 2028 Current Closing Date for Applications:Jan 07, 2028 Archive Date:Feb 12, 2028 Estimated Total Program Funding: Eligible Applicants:City or township governments Independent school districts Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments For profit organizations other than small businesses Private institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Additional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
## Additional Information Agency Name:National Institutes of Health Description:The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice.
Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets.
The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies. Link to Additional Information:https://grants. nih.
gov/grants/guide/pa-files/PAR-25-024. html Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: ## Similar Opportunities (identified by AI)
According to the current listing, eligibility includes: See Opportunity Website for specific eligibility; generally, academic and medical research institutions, as well as non-profits with a research focus, are eligible. Confirm the full requirements in the official notice before applying.
Applications for Grants for Research on Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional) are due October 20, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Grants for Research on Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional) is funded by National Institutes of Health. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
NIH R25 Summer Research Education Experience Program is a grant from the National Institutes of Health (NIH) that funds universities and institutions of higher education to provide summer research experiences in environmental health sciences to high school students, college undergraduates, and science teachers. Administered through the National Institute of Environmental Health Sciences (NIEHS), the program aims to attract young people to scientific careers and help teachers communicate about the scientific process more effectively. Eligible applicants are U.S. institutions eligible for NIH grants. The application deadline was March 17, 2026.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
The NIH Extramural Loan Repayment Program pays up to $50,000 a year against educational debt at roughly a 50% success rate — better odds than almost any NIH research grant. For FY2027 the six extramural subcategories collapse into three: L30, L40, and L70. Applicants who would have used L32, L50, or L60 must now pick a new lane. Here is the crosswalk, the 20% debt-to-salary rule, and why the consolidation changes how you frame the research.
Read articleNOT-OD-26-098 bars K award funds from supporting clinical trials, feasibility studies, and ancillary studies for due dates on or after October 12, 2027, and retires the Independent Clinical Trial Required K NOFOs. NIH has no replacement mechanism yet — only an RFI closing September 30, 2026. Here is what the policy actually says, who it hits, and how to sequence around it.
Read articleNIH proposed on August 14 to withhold overall impact scores and percentiles from applicants, replacing them with three bands: Most competitive, Competitive, Not discussed. Paylines already vanished in January. Here is what applicants actually lose, what survives in the summary statement, and how to rebuild a resubmission decision rule without a number.
Read article